1
|
Trabattoni D, Gili S, Calligaris G, Teruzzi G, Troiano S, Ravagnani P, Santagostino Baldi G, Montorsi P. Patent foramen ovale closure with the Occlutech Figulla flex II device: A long-term (up to 10-years) follow-up. Int J Cardiol 2023; 387:131116. [PMID: 37301447 DOI: 10.1016/j.ijcard.2023.06.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2023] [Accepted: 06/07/2023] [Indexed: 06/12/2023]
Abstract
BACKGROUND Percutaneous closure represents the first line of treatment in patients with cryptogenic stroke and documented patent foramen ovale (PFO). Scarce data report the long-term outcomes of patients undergoing PFO closure with the Figulla Flex II device (Occlutech, Germany). METHODS Consecutive patients undergoing PFO closure with a Figulla Flex II device at a single, high-volume Institution were included. Baseline clinical and procedural features were collected and patients were followed up for up to 10 years. The device's long-term safety was assessed, as well as mortality, recurrent cerebrovascular events, new-onset atrial fibrillation (AF) and residual shunt. RESULTS Overall, 442 patients were included. The main indication for PFO closure was cryptogenic stroke/transitory ischemic attack (65.5%), followed by migraine (21.7%), silent lesions at MRI (10.8%), and decompression disease (2.0%). Atrial septal aneurysm was present in 20.8% of cases, Eustachian valve in 9.0%, Chiari network in 19.9%. The most frequently implanted device was the 23/25 mm (49.5% of cases). One procedural failure due to device embolization; in-hospital complications occurred in 15 cases (3.4%; 4 minor access site complications, 11 transient supraventricular tachycardias (SVT)/AF). After a follow-up of 9.2 years, 2 patients suffered recurrent TIA (with no residual R-L shunt detected). A moderate or severe residual shunt was observed in 3 patients after discharge. CONCLUSIONS Figulla Flex II devices for PFO closure are associated with high procedural success and low incidence of adverse events even at long-term follow-up.
Collapse
Affiliation(s)
- Daniela Trabattoni
- Centro Cardiologico "Monzino", IRCCS, Department of Cardiovascular Sciences, University of Milan, Italy.
| | - Sebastiano Gili
- Centro Cardiologico "Monzino", IRCCS, Department of Cardiovascular Sciences, University of Milan, Italy
| | - Giuseppe Calligaris
- Centro Cardiologico "Monzino", IRCCS, Department of Cardiovascular Sciences, University of Milan, Italy
| | - Giovanni Teruzzi
- Centro Cardiologico "Monzino", IRCCS, Department of Cardiovascular Sciences, University of Milan, Italy
| | - Sarah Troiano
- Centro Cardiologico "Monzino", IRCCS, Department of Cardiovascular Sciences, University of Milan, Italy
| | - Paolo Ravagnani
- Centro Cardiologico "Monzino", IRCCS, Department of Cardiovascular Sciences, University of Milan, Italy
| | - Giulia Santagostino Baldi
- Centro Cardiologico "Monzino", IRCCS, Department of Cardiovascular Sciences, University of Milan, Italy
| | - Piero Montorsi
- Centro Cardiologico "Monzino", IRCCS, Department of Cardiovascular Sciences, University of Milan, Italy
| |
Collapse
|
2
|
Safety of Occlutech Septal Occluder ACCELL Flex II for Transcatheter Closure of Secundum Atrial Septal Defects in Children: A Long-Term Follow-Up. J Interv Cardiol 2022; 2022:8886813. [PMID: 35069039 PMCID: PMC8752296 DOI: 10.1155/2022/8886813] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2020] [Revised: 10/28/2021] [Accepted: 11/03/2021] [Indexed: 11/18/2022] Open
Abstract
Objectives. To assess the long-term safety and efficacy of the Occlutech® ACCELL® Flex II device used for atrial septal defect (ASD) closure. This device differs from the regular device by having two very thin patches that are made of polyethylene terephthalate (PET). These patches enhance faster sealing of the defect. Background. Transcatheter closure has become the method of choice to manage most patients with secundum ASDs. There are different types of devices. The regular Occlutech device used to close an ASD is called the Occlutech Figulla Flex II. A newer modification of this device (Occlutech® ACCELL® Flex II) has been designed to eliminate/reduce thrombus formation and to enhance faster sealing. Methods. Thirty patients were followed up after occlusion of secundum ASD using the Occlutech® ACCELL® Flex II Device. The follow-up period ranged from 5.2–5.5 years with median of 5.3 years. Detailed history and full clinical examination, twelve-lead electrocardiogram (ECG), plain chest radiograph, and full 2D transthoracic echocardiography (TTE) were performed at discharge, at one month, six months, and yearly thereafter. Results. The mean age of the study group at the last follow-up was 10.4 ± 4.6 years, with 63.3% (nineteen patients) females. There were no residual shunts or complications encountered immediately after the procedure and at the latest follow-up. Conclusion. This study confirmed the transcatheter closure (TCC) of secundum ASDs using the Occlutech® ACCELL® Flex II device to be safe and effective with no complications detected in children and adolescents.
Collapse
|
3
|
Nakayama R, Takaya Y, Akagi T, Watanabe N, Miki T, Nakagawa K, Toh N, Ito H. Efficacy and safety of atrial septal defect closure using Occlutech Figulla Flex II compared with Amplatzer Septal Occluder. Heart Vessels 2021; 36:704-709. [PMID: 33386412 DOI: 10.1007/s00380-020-01739-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Accepted: 11/20/2020] [Indexed: 11/25/2022]
Abstract
Few studies have reported the efficacy of Occlutech Figulla Flex II (FFII) device compared with Amplatzer Septal Occluder (ASO) device. The aim of this study was to examine the efficacy and safety of FFII compared with ASO for transcatheter atrial septal defect (ASD) closure. We retrospectively evaluated 190 patients using FFII and 190 patients using ASO who underwent transcatheter ASD closure. ASD characteristics were evaluated by transesophageal echocardiography. The prevalence of procedural complications, including erosion, device embolization, stroke, and new-onset atrial arrhythmia, and the presence of a residual shunt were evaluated between the two groups during 12-month follow-up. FFII was used more frequently than ASO in patients with a deficient aortic rim or septal malalignment (P = 0.02, P < 0.01, respectively). The procedural complications of erosion, device embolization, and stroke did not occur in any patients. New-onset atrial arrhythmia occurred in 3 patients of the FFII group and 4 patients of the ASO group, and the difference between the two groups was not significant (P = 0.70). A large residual shunt (≥ 3 mm) was observed in 6 patients of the FFII group and 5 patients of the ASO group, and the difference between the two groups was not significant (P = 0.76). FFII was used frequently in patients with high-risk ASD morphology; however, there was no difference in the prevalence of procedural complications or efficacy between patients using FFII and those using ASO.
Collapse
Affiliation(s)
- Rie Nakayama
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan
| | - Yoichi Takaya
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
| | - Teiji Akagi
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan
| | - Nobuhisa Watanabe
- Division of Medical Support, Okayama University Hospital, Okayama, Japan
| | - Takashi Miki
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan
| | - Koji Nakagawa
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan
| | - Norihisa Toh
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan
| | - Hiroshi Ito
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan
| |
Collapse
|
4
|
Microtransesophageal Echocardiographic Guidance during Percutaneous Interatrial Septal Closure without General Anaesthesia. J Interv Cardiol 2020; 2020:1462140. [PMID: 32982607 PMCID: PMC7492935 DOI: 10.1155/2020/1462140] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2020] [Revised: 07/30/2020] [Accepted: 08/31/2020] [Indexed: 11/23/2022] Open
Abstract
Objective To study the safety and efficacy of microtransesophageal echocardiography (micro-TEE) and TEE during percutaneous atrial septal defect (ASD) and patent foramen ovale (PFO) closure. Background TEE has proven to be safe during ASD and PFO closure under general anaesthesia. Micro-TEE makes it possible to perform these procedures under local anaesthesia. We are the first to describe the safety and efficacy of micro-TEE for percutaneous closure. Methods All consecutive patients who underwent ASD and PFO closure between 2013 and 2018 were included. The periprocedural complications were registered. Residual shunts were diagnosed using transthoracic contrast echocardiography (TTCE). All data were compared between the use of TEE or micro-TEE within the ASD and PFO groups separately. Results In total, 82 patients underwent ASD closure, 46 patients (49.1 ± 15.0 years) with TEE and 36 patients (47.8 ± 12.1 years) using micro-TEE guidance. Median device diameter was, respectively, 26 mm (range 10–40 mm) and 27 mm (range 10–35 mm). PFO closure was performed in 120 patients, 55 patients (48.6 ± 9.2 years, median device diameter 25 mm, range 23–35 mm) with TEE and 65 patients (mean age 51.0 ± 11.8 years, median device diameter 27 mm, range 23–35 mm) using micro-TEE. There were no major periprocedural complications, especially no device embolizations within all groups. Six months after closure, there was no significant difference in left-to-right shunt after ASD closure and no significant difference in right-to-left shunt after PFO closure using TEE or micro-TEE. Conclusion Micro-TEE guidance without general anaesthesia during percutaneous ASD and PFO closure is as safe as TEE, without a significant difference in the residual shunt rate after closure.
Collapse
|
5
|
Shi D, Kang Y, Zhang G, Gao C, Lu W, Zou H, Jiang H. Biodegradable atrial septal defect occluders: A current review. Acta Biomater 2019; 96:68-80. [PMID: 31158496 DOI: 10.1016/j.actbio.2019.05.073] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2018] [Revised: 05/21/2019] [Accepted: 05/29/2019] [Indexed: 01/11/2023]
Abstract
Atrial septal defect (ASD) is a common structural congenital heart disease. With the development of interventional closure devices and transcatheter techniques, interventional closure therapy has become the most well-accepted therapeutic alternative worldwide, as it offers a number of advantages over conventional therapies such as improved safety, easier operation, lower complication rates and invasiveness, and shorter anesthetic time and hospitalizations. During the past decades, various types of occluders based on nondegradable shape memory alloys have been used in clinical applications. Considering that the permanent existence of foreign nondegradable materials in vivo can cause many potential complications in the long term, the research and development of biodegradable occluders has emerged as a crucial issue for interventional treatment of ASD. This review aims to summarize partially or fully biodegradable occlusion devices currently reported in the literature from the aspects of design, construction, and evaluation of animal experiments. Furthermore, a comparison is made on the advantages and disadvantages of the materials used in biodegradable ASD occlusion devices, followed by an analysis of the problems and limitations of the occlusion devices. Finally, several strategies are proposed for future development of biodegradable cardiac septal defect occlusion devices. STATEMENT OF SIGNIFICANCE: Although occlusion devices based on nondegradable alloys have been widely used in clinical applications and saved numerouspatients, biodegradable occlusion devices may offer some advantages such as fewer complications, acceptable biocompatibility, and particularly temporary existence, thereby leaving "native" tissue behind, which will certainly become the development trend in the long term. This review summarizes almost all partially or fully biodegradable occlusion devices currently reported in the literature from the aspects of design, construction, and evaluation of animal experiments. Furthermore, a comparison is made on the advantages and disadvantages of the materials used in biodegradable ASD occlusion devices, followed by an analysis of the problems and limitations of the occlusion devices. Finally, several strategies are proposed for future development of biodegradable cardiac septal defect occlusion devices.
Collapse
|
6
|
Bhattacharjya S, Pillai LS, Doraiswamy V, Satyanarayana RM, Chandrasekaran R, Pavithran S, Sivakumar K. Prospective concurrent head-to head comparison of three different types of nitinol occluder device for transcatheter closure of secundum atrial septal defects. EUROINTERVENTION 2019; 15:e321-e328. [DOI: 10.4244/eij-d-18-01016] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
7
|
Snijder RJR, Renes LE, Suttorp MJ, Ten Berg JM, Post MC. Percutaneous patent foramen ovale closure using the Occlutech Figulla device: More than 1,300 patient-years of follow up. Catheter Cardiovasc Interv 2019; 93:1080-1084. [PMID: 30461175 DOI: 10.1002/ccd.27984] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/14/2018] [Revised: 10/22/2018] [Accepted: 10/29/2018] [Indexed: 11/07/2022]
Abstract
OBJECTIVE To evaluate the safety and efficacy of the Occlutech patent foramen ovale (PFO) device at long-term follow-up (FU). BACKGROUND The Occlutech device has been proven safe and effective six-months after percutaneous PFO closure. We describe the safety and efficacy after more than 1,300 patient-years of FU. METHODS All consecutive patients who underwent PFO closure between October 2008 and December 2015 were included. All complications were registered. Residual right-to-left shunt (RLS) was diagnosed using contrast transthoracic echocardiography and graded as minimal, moderate, or severe. RESULTS In total, 250 patients (mean age 53.5 ± 10.7 years, 46.8% female) underwent percutaneous PFO closure using the Occlutech device. Mean FU was 5.9 ± 1.8 years, a total of 1,345 patient-years. Transient ischemic attack (TIA) or stroke was the main indication for closure (89.6%). Implantation was successful in 100%, no major complications occurred. Minor complications were inguinal hematoma in 16 patients (6.4%), pericardial effusion without the need for intervention in one patient (0.4%) and a supraventricular tachycardia in one patient (0.4%). A moderate or large shunt at one-year follow up was present in 5.9%. A cerebrovascular vascular event occurred in 2.0% at 1-year FU (four TIA, one stroke) and in 7.4% at long-term FU (nine TIA, eight stroke). The total cerebrovascular event rate (TIA and CVA) was 0.02% per patient-year of FU, with a stroke rate of 0.01%. CONCLUSION The Occlutech device appears to be safe at long-term FU with a very low annual cerebrovascular event rate and a low moderate to large shunt rate at 1-year FU.
Collapse
Affiliation(s)
- Roel J R Snijder
- Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
| | - Laura E Renes
- Department of Emergency Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands
| | - Maarten Jan Suttorp
- Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
| | - Jurrien M Ten Berg
- Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
| | - Martijn C Post
- Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
| |
Collapse
|
8
|
Almanla A, Charafeddine F, Abutaqa M, Mustafa H, Tabbakh A, Hussein HB, Sawaya F, El-Rassi I, Arabi M, Bulbul Z, Bitar F. Transcatheter Closure of Atrial Septal Defects: Comparable Experience and Outcomes Between Developing and Developed Countries. Pediatr Cardiol 2019; 40:610-615. [PMID: 30607441 DOI: 10.1007/s00246-018-2034-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Accepted: 12/05/2018] [Indexed: 10/27/2022]
Abstract
Atrial septal defect (ASD) is one of the most common congenital heart defects. Transcatheter device closure of ASDs is safe and effective with most of the reported data being described from developed countries. To evaluate the short and mid-term results and experience of device closure of ASDs at a tertiary center in a developing country and compare it to that from developed countries. Retrospective study based on data collection from all patients who have undergone transcatheter percutaneous device closure for ASD from January 2005 until December 2017 at the Children's Heart Center at the American University of Beirut, Medical Center, Lebanon. During the study period, a total of 254 cardiac catheterizations were performed for device closure of ASDs. The mean age of the patients was 18 ± 17.9 years with 37% being less than 6 years of age. Females were 54%. Defect size ranged from 7 to 37 mm and device size ranged from 8 to 40 mm. The procedure was executed with a success rate of 96%. Five patients had device embolization (2%); in one patient the device was snared and for the remainder the devices were removed surgically. None of the study patients had thrombus formation, neurological complications, bacterial endocarditis, or cardiac erosions. There was no mortality. Device closure of ASDs at our tertiary center in a developing country has an effective and safe profile with excellent results and low complications rates, which compare favorably to those reported from centers in developed countries.
Collapse
Affiliation(s)
- Ahmad Almanla
- Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center (AUBMC), Beirut, Lebanon
| | - Fatme Charafeddine
- Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center (AUBMC), Beirut, Lebanon.,Children's Heart Center, AUBMC, Beirut, Lebanon
| | - Mohamad Abutaqa
- Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center (AUBMC), Beirut, Lebanon.,Children's Heart Center, AUBMC, Beirut, Lebanon
| | - Hala Mustafa
- Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center (AUBMC), Beirut, Lebanon
| | - Anas Tabbakh
- Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center (AUBMC), Beirut, Lebanon.,Children's Heart Center, AUBMC, Beirut, Lebanon
| | - Haytham Bou Hussein
- Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center (AUBMC), Beirut, Lebanon.,Children's Heart Center, AUBMC, Beirut, Lebanon
| | | | | | - Mariam Arabi
- Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center (AUBMC), Beirut, Lebanon.,Children's Heart Center, AUBMC, Beirut, Lebanon
| | - Ziad Bulbul
- Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center (AUBMC), Beirut, Lebanon.,Children's Heart Center, AUBMC, Beirut, Lebanon
| | - Fadi Bitar
- Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center (AUBMC), Beirut, Lebanon. .,Children's Heart Center, AUBMC, Beirut, Lebanon. .,Children's Heart Center, Department of Pediatrics and Adolescent Medicine, American University of Beirut, PO Box 11-0236, 1107 2020, Riad El Solh, Beirut, Lebanon.
| |
Collapse
|
9
|
Kim AY, Jung SY, Chang JY, Jung JW, Choi JY. Early to Mid-Term Follow-Up Outcomes of Percutaneous Closure of Atrial Septal Defects Using Recent Generation Devices: a Single-Center Experience. Korean Circ J 2018; 49:326-335. [PMID: 30808079 PMCID: PMC6428945 DOI: 10.4070/kcj.2018.0278] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Accepted: 11/27/2018] [Indexed: 11/11/2022] Open
Abstract
Background and Objectives This study aimed to describe our early to mid-term experience with transcatheter atrial septal defect (ASD) closure using the Occlutech Figulla® Flex II device (FSO), Gore® Cardioform septal occluder (GSO), and Amplatzer® septal occluder (ASO) after they were first approved in Korea in 2014, and to compare the three aforementioned kinds of ASD closure devices. Methods Between September 2014 and August 2016, 267 patients underwent transcatheter ASD closure in our institution. Baseline characteristics, hemodynamic features, comorbidities, and procedural success and complication rates were analyzed retrospectively. The unpaired Student t-test or variance analysis was used in the statistical analysis. Results The FSO was most commonly used (n=152, 56.9%), followed by the ASO (n=98, 36.7%) and GSO (n=17, 6.4%). Baseline characteristics and hemodynamic features were similar between the devices, except that the defect size and pulmonary flow-to-systemic flow ratio were lower in the GSO group than in the other groups. Overall, the procedural success rate remained at 100%, and major complication rate was <1%. No late complication occurred during the follow-up. Conclusions The FSO and GSO are feasible, safe options for use in transcatheter ASD closure, and they are comparable to the ASO.
Collapse
Affiliation(s)
- Ah Young Kim
- Division of Pediatric Cardiology, Center for Congenital Heart Disease, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Se Yong Jung
- Division of Pediatric Cardiology, Center for Congenital Heart Disease, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Jenny Yeonsoo Chang
- Department of Biological Basis of Behavior, College of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA
| | - Jo Won Jung
- Division of Pediatric Cardiology, Center for Congenital Heart Disease, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Jae Young Choi
- Division of Pediatric Cardiology, Center for Congenital Heart Disease, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea.
| |
Collapse
|
10
|
Kenny D, Eicken A, Dähnert I, Boudjemline Y, Sievert H, Schneider MBE, Gori T, Hijazi ZM. A randomized, controlled, multi‐center trial of the efficacy and safety of the Occlutech Figulla Flex‐II Occluder compared to the Amplatzer Septal Occluder for transcatheter closure of secundum atrial septal defects. Catheter Cardiovasc Interv 2018; 93:316-321. [DOI: 10.1002/ccd.27899] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2016] [Revised: 08/29/2018] [Accepted: 08/29/2018] [Indexed: 11/09/2022]
Affiliation(s)
- Damien Kenny
- Department of CardiologyOur Lady's Children's Hospital Dublin Ireland
| | | | - Ingo Dähnert
- Department of Pediatric Cardiology Heart CentreUniversity of Leipzig Leipzig Germany
| | - Younes Boudjemline
- Department of Pediatric Cardiology, Centre de reference des Malformations Cardiaques Congénitales ComplexesNecker Hospital Paris France
| | - Horst Sievert
- CardioVascular Center Frankfurt, FrankfurtGermany & Anglia Ruskin University Chelmsford United Kingdom
| | - Martin BE Schneider
- Department of Pediatric Cardiology, Charitè Medical CenterHumboldt University Berlin Germany
| | - Tommaso Gori
- Zentrum für Kardiologie, Kardiologie IUniversity Medical Center, and DZHK Standort Rhein‐Main Mainz Germany
| | - Ziyad M. Hijazi
- Sidra Cardiovascular Center of ExcellenceWeil Cornell Medical College Doha Qatar
| | | |
Collapse
|
11
|
Araszkiewicz A, Sławek S, Trojnarska O, Lesiak M, Grygier M. Interventional closure of patent foramen ovale with Nit-occlud® device in prevention of recurrent neurologic events-Long-term results. Catheter Cardiovasc Interv 2017; 92:159-164. [DOI: 10.1002/ccd.27386] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2017] [Revised: 09/12/2017] [Accepted: 10/05/2017] [Indexed: 12/29/2022]
Affiliation(s)
| | - Sylwia Sławek
- Department of Cardiology; Poznan University of Medical Sciences; Poland
| | - Olga Trojnarska
- Department of Cardiology; Poznan University of Medical Sciences; Poland
| | - Maciej Lesiak
- Department of Cardiology; Poznan University of Medical Sciences; Poland
| | - Marek Grygier
- Department of Cardiology; Poznan University of Medical Sciences; Poland
| |
Collapse
|
12
|
Trabattoni D, Gaspardone A, Sgueglia GA, Fabbiocchi F, Gioffrè G, Montorsi P, Calligaris G, Iamele M, De Santis A, Bartorelli AL. AMPLATZER versus Figulla occluder for transcatheter patent foramen ovale closure. EUROINTERVENTION 2017; 12:2092-2099. [PMID: 27993750 DOI: 10.4244/eij-d-15-00499] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
AIMS The aim of this observational study was to compare acute and 12-month results of percutaneous closure of patent foramen ovale (PFO) with two occluder devices. METHODS AND RESULTS Between June 2007 and October 2014, 406 consecutive patients (48.1±13.3 years, 243 women) underwent percutaneous PFO closure with either the AMPLATZER (n=179) or the Figulla (n=227) device after a stroke or a transient ischaemic attack ascribed to the PFO. A right-to-left shunt grade >1 was previously detected in all patients and atrial septal aneurysm was present in 111 (27.5%) patients. Patients were followed up with a contrast transthoracic echocardiogram and clinically at 24 hours, six months, and 12 months after the procedure. A high procedural success was observed in both groups. Despite a trend towards a higher incidence of acute residual shunt immediately after device deployment among Figulla occluder patients, a residual grade ≥2 right-to-left shunt was observed in 4.5% of patients, independently of the device used for PFO closure. The only difference reported after Figulla device implantation was a lower rate of supraventricular arrhythmias (9% vs. 17%, p=0.02). CONCLUSIONS According to this two-centre study, PFO closure appears safe and effective with the Figulla occluder as well as with the AMPLATZER device.
Collapse
Affiliation(s)
- Daniela Trabattoni
- Centro Cardiologico "Monzino" IRCCS and Department of Cardiovascular Sciences, University of Milan, Milan, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Neuser J, Akin M, Bavendiek U, Kempf T, Bauersachs J, Widder JD. Mid-term results of interventional closure of patent foramen ovale with the Occlutech Figulla ® Flex II Occluder. BMC Cardiovasc Disord 2016; 16:217. [PMID: 27832757 PMCID: PMC5103606 DOI: 10.1186/s12872-016-0391-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Accepted: 11/04/2016] [Indexed: 11/16/2022] Open
Abstract
Background Patients with a patent foramen ovale (PFO) who suffered from stroke, TIA or peripheral paradoxical embolism are at substantial risk for recurrent neurologic events and in need for secondary prevention. Interventional closure of PFO has been performed for over 20 years. Numerous devices have been developed and used for treatment. We investigated PFO closure with the third generation Occlutech Figulla® Flex II Occluder device. Methods Between 2012 and 2015 57 patients (mean age 47.3 ± 1.5 years) who had suffered from a thromboembolic event of unknown cause underwent transcatheter PFO closure with the Occlutech Figulla® Flex II Occluder at our department. 68.4 % of all patients had suffered from cryptogenic stroke, while TIA had occurred in 28.1 %. Almost all patients were diagnosed with an atrial septum aneurysm (90.9 %) and a severe right-to-left shunt grade 3: >20 microbubbles (92.0 %). Follow-up was done 6 months post intervention by clinical examination and transesophageal contrast echocardiography. Results No major periprocedural or in-hospital complication occurred. Closure was sufficient with no residual right-to-left shunt in 94.4 % of all patients at 6 months post implantation and only minimal residual shunt in three cases. There were no thrombotic formations associated to the occluder device. Atrial fibrillation occurred in one patient and a recurrent cerebral ischemic event was seen in one patient, who suffered from another TIA. Conclusions The Occlutech Figulla® Flex II Occluder device and its delivery system is safe and provides sufficient closure of PFO in patients who suffered from cryptogenic stroke, TIA or paradoxical peripheral embolism.
Collapse
Affiliation(s)
- Jonas Neuser
- Department of Cardiology und Angiology, Hannover Medical School, Hannover, D-30625, Germany
| | - Muharrem Akin
- Department of Cardiology und Angiology, Hannover Medical School, Hannover, D-30625, Germany
| | - Udo Bavendiek
- Department of Cardiology und Angiology, Hannover Medical School, Hannover, D-30625, Germany
| | - Tibor Kempf
- Department of Cardiology und Angiology, Hannover Medical School, Hannover, D-30625, Germany
| | - Johann Bauersachs
- Department of Cardiology und Angiology, Hannover Medical School, Hannover, D-30625, Germany
| | - Julian D Widder
- Department of Cardiology und Angiology, Hannover Medical School, Hannover, D-30625, Germany.
| |
Collapse
|
14
|
Nassif M, Abdelghani M, Bouma BJ, Straver B, Blom NA, Koch KT, Tijssen JGP, Mulder BJM, de Winter RJ. Historical developments of atrial septal defect closure devices: what we learn from the past. Expert Rev Med Devices 2016; 13:555-68. [PMID: 27112301 DOI: 10.1080/17434440.2016.1182860] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
INTRODUCTION Since King and Mills' pioneering work in percutaneous closure devices of secundum atrial septal defects (ASD) four decades ago, developments in device shape, material and implantation technique led to adoption of percutaneous ASD closure as current treatment of choice. Not only was the feasibility of such a percutaneous procedure tested altogether, but pursuing the ideal device in terms of safety and efficacy became priority. AREAS COVERED In this review we present the historical development of ASD devices in design, material and technique with clinical data, and provide the future perspectives in percutaneous ASD closures. EXPERT OPINION An 'ideal device' requires complete defect closure with negligible risk of complications using a safe, straightforward delivery technique with repositioning and retrieving properties. Some of the devices currently at hand come close to fulfilling these criteria, however none seem to provide those prerequisites completely. By understanding how challenges in device development were overcome in the past, new insights into future improvements are given.
Collapse
Affiliation(s)
- Martina Nassif
- a Department of Cardiology, Academic Medical Center , University of Amsterdam , Amsterdam , The Netherlands
| | - Mohammad Abdelghani
- a Department of Cardiology, Academic Medical Center , University of Amsterdam , Amsterdam , The Netherlands
| | - Berto J Bouma
- a Department of Cardiology, Academic Medical Center , University of Amsterdam , Amsterdam , The Netherlands
| | - Bart Straver
- b Department of Pediatric Cardiology, Academic Medical Center , University of Amsterdam , Amsterdam , The Netherlands
| | - Nico A Blom
- b Department of Pediatric Cardiology, Academic Medical Center , University of Amsterdam , Amsterdam , The Netherlands
| | - Karel T Koch
- a Department of Cardiology, Academic Medical Center , University of Amsterdam , Amsterdam , The Netherlands
| | - Jan G P Tijssen
- a Department of Cardiology, Academic Medical Center , University of Amsterdam , Amsterdam , The Netherlands
| | - Barbara J M Mulder
- a Department of Cardiology, Academic Medical Center , University of Amsterdam , Amsterdam , The Netherlands.,c Interuniversity Cardiology Institute of the Netherlands (ICIN) , Utrecht , The Netherlands
| | - Robbert J de Winter
- a Department of Cardiology, Academic Medical Center , University of Amsterdam , Amsterdam , The Netherlands
| |
Collapse
|
15
|
Haas NA, Soetemann DB, Ates I, Baspinar O, Ditkivskyy I, Duke C, Godart F, Lorber A, Oliveira E, Onorato E, Pac F, Promphan W, Riede FT, Roymanee S, Sabiniewicz R, Shebani SO, Sievert H, Tin D, Happel CM. Closure of Secundum Atrial Septal Defects by Using the Occlutech Occluder Devices in More Than 1300 Patients: The IRFACODE Project: A Retrospective Case Series. Catheter Cardiovasc Interv 2016; 88:571-581. [DOI: 10.1002/ccd.26497] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2015] [Accepted: 02/13/2016] [Indexed: 11/09/2022]
Affiliation(s)
- Nikolaus A. Haas
- Department for Congenital Heart Defects; Heart and Diabetes Centre North Rhine Westphalia, Ruhr University Bochum; Germany
- Department of Pediatric Cardiology and Intensive Care; Ludwig Maximilians University Munich Campus; Munich Germany
| | - Dagmar B. Soetemann
- Department for Congenital Heart Defects; Heart and Diabetes Centre North Rhine Westphalia, Ruhr University Bochum; Germany
| | - Ismail Ates
- Department of Cardiology; Asfendiyarov Kazakh National Medical University; Almaty Kazakhistan
| | - Osman Baspinar
- Department of Pediatric Cardiology; Faculty of Medicine, University of Gaziantep; Turkey
| | | | | | - Francois Godart
- Département De Cardiologie Infantile Et Congénitale; Centre Hospitalier Régional Et Universitaire De Lille, Faculté De Médecine Lille 2; France
| | - Avraham Lorber
- Division of Pacing and Electrophysiology; Rambam Health Care Campus and Bruce Rappaport, Faculty of Medicine; Haifa Israel
| | - Edmundo Oliveira
- Hospital Das Clinicas, Universida De Federal De Minas Gerais, Belo Horizonte; Minas Gerais Brazil
| | - Eustaquio Onorato
- Cardiovascular Department; Humanitas Gavazzeni Institute; Bergamo Italy
| | - Feyza Pac
- Department of Pediatric Cardiology; Türkiye, Yüksekİhtisas, Training and Research Hospital; Ankara Turkey
| | - Worakan Promphan
- Pediatric Cardiology Unit, Queen Sirikit National Institute of Child Health (QSNICH); Bangkok Thailand
| | - Frank-Thomas Riede
- Department of Pediatric Cardiology; Heart Center, University of Leipzig; Leipzig Germany
| | - Supaporn Roymanee
- Department of Pediatrics; Pediatric Cardiology Unit, Prince of Songkla University; Thailand
| | - Robert Sabiniewicz
- Department of Pediatric Cardiology and Congenital Heart Diseases; Medical University Gdansk; Poland
| | | | | | - Do Tin
- Department of Cardiology, Children's Hospital and, Department of Pediatric; Medicine and Pharmacy University of Ho Chi Minh City; Vietnam
| | - Christoph M. Happel
- Department for Congenital Heart Defects; Heart and Diabetes Centre North Rhine Westphalia, Ruhr University Bochum; Germany
| |
Collapse
|
16
|
Pedra CAC, Pedra SF, Costa RN, Ribeiro MS, Nascimento W, Campanhã LOS, Santana MVT, Jatene IB, Assef JE, Fontes VF. Mid-Term Outcomes after Percutaneous Closure of the Secundum Atrial Septal Defect with the Figulla-Occlutech Device. J Interv Cardiol 2016; 29:208-15. [PMID: 26927945 DOI: 10.1111/joic.12284] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
OBJECTIVES To evaluate the mid-term outcomes after percutaneous closure of the secundum atrial septal defects (ASD) using the Figulla-Occlutech device (FOD). BACKGROUND Transcatheter closure has become the method of choice for most patients with ASD. Although the FOD may have some advantageous characteristics there is a paucity of data on later outcomes after the use of this relatively new device. METHODS Observational, single arm study including 200 non-consecutive patients who underwent ASD closure between 04/09 and 07/15 in 2 centers. Device performance, deployment technique, and immediate and mid-term outcomes were assessed. RESULTS Median age and weight were 24 years (4-72) and 58 kg (15-92), respectively. Single defects were observed in 171 patients (median size of 19 mm). The remainder had multiple or multifenestrated defects. Implantation of FOD (median size of 24 mm) was successful in all (99%), but 2 patients (1 with deficient postero-inferior rim; 1 with a large ASD for the size of the child). Embolization with device retrieval occurred in 2 (1%). Median follow-up of 36 months was obtained in 172 patients. Serial echocardiographic assessment showed complete closure in all but 2 patients, in whom an additional small non-significant posterior defect was purposely left untouched. There have been no episodes of late arrhythmias, device embolization, cardiac erosion, endocarditis, thromboembolism, wire fracture, or death. CONCLUSIONS Transcatheter closure of ASDs in older children, adolescents, and adults using the FOD was highly successful in a wide range of anatomical scenarios with high closure rates and no complications in mid-term follow-up.
Collapse
Affiliation(s)
- Carlos A C Pedra
- Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.,Hospital do Coração da Associação Sanatório Sírio, São Paulo, Brazil
| | - Simone F Pedra
- Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.,Hospital do Coração da Associação Sanatório Sírio, São Paulo, Brazil
| | - Rodrigo N Costa
- Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.,Hospital do Coração da Associação Sanatório Sírio, São Paulo, Brazil
| | - Marcelo S Ribeiro
- Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.,Hospital do Coração da Associação Sanatório Sírio, São Paulo, Brazil
| | - Wanda Nascimento
- Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.,Hospital do Coração da Associação Sanatório Sírio, São Paulo, Brazil
| | - Luis Otávio S Campanhã
- Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.,Hospital do Coração da Associação Sanatório Sírio, São Paulo, Brazil
| | | | - Ieda B Jatene
- Hospital do Coração da Associação Sanatório Sírio, São Paulo, Brazil
| | - Jorge E Assef
- Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil
| | - Valmir F Fontes
- Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.,Hospital do Coração da Associação Sanatório Sírio, São Paulo, Brazil
| |
Collapse
|
17
|
Polzin A, Dannenberg L, Sophia Popp V, Kelm M, Zeus T. Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale/ atrium septum defect closure. Platelets 2015; 27:317-21. [PMID: 26556101 DOI: 10.3109/09537104.2015.1096335] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The optimal antiplatelet therapy after patent foramen ovale (PFO)/ atrium septum defect (ASD) closure is a matter of discussion. It is challenging as inter-individual responses to antiplatelet medication vary significantly and common complications are bleeding and ischemic events. In this study, we aimed to analyze the incidence of high on-treatment platelet reactivity (HTPR) to antiplatelet medication in patients undergoing PFO/ASD closure as well as clinical complications and thrombus formation on the occluder during six-month follow-up. This hypothesis generating pilot study was observed, which included 140 patients undergoing PFO/ASD closure. The primary endpoint was pharmacodynamic response to antiplatelet medication. A composite of death, myocardial infarction, bleeding, stroke and thrombus formation on the occluder during six-month follow-up was the secondary endpoint. HTPR to clopidogrel was analyzed using the vasodilator-stimulated protein phosphorylation (VASP), HTPR to aspirin by light-transmission aggregometry (LTA). In 71% of patients HTPR to clopidogrel was detected, HTPR to aspirin in only 4%. We observed 12 complications, 9 bleeding events (including 3 major bleeding events) and 3 transient ischemic attacks. No stroke and no thrombus formation on the occluder occurred. The primary endpoint was not associated with the secondary endpoint. The incidence of HTPR to clopidogrel in PFO/ASD closure patients is very high. Despite this high incidence, no stroke or thrombus formation on the occluder occurred at all. This leads to the hypothesis, that the benefit of additional clopidogrel medication is questionable and has to be investigated in large-scale clinical trials.
Collapse
Affiliation(s)
- Amin Polzin
- a Division of Cardiology, Pulmonology, and Vascular Medicine , Heinrich Heine University Medical Center Düsseldorf , Düsseldorf , Germany
| | - Lisa Dannenberg
- a Division of Cardiology, Pulmonology, and Vascular Medicine , Heinrich Heine University Medical Center Düsseldorf , Düsseldorf , Germany
| | - Valérie- Sophia Popp
- a Division of Cardiology, Pulmonology, and Vascular Medicine , Heinrich Heine University Medical Center Düsseldorf , Düsseldorf , Germany
| | - Malte Kelm
- a Division of Cardiology, Pulmonology, and Vascular Medicine , Heinrich Heine University Medical Center Düsseldorf , Düsseldorf , Germany
| | - Tobias Zeus
- a Division of Cardiology, Pulmonology, and Vascular Medicine , Heinrich Heine University Medical Center Düsseldorf , Düsseldorf , Germany
| |
Collapse
|
18
|
Roymanee S, Promphan W, Tonklang N, Wongwaitaweewong K. Comparison of the Occlutech ® Figulla ® septal occluder and Amplatzer ® septal occluder for atrial septal defect device closure. Pediatr Cardiol 2015; 36:935-41. [PMID: 25633819 DOI: 10.1007/s00246-015-1103-y] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/23/2014] [Accepted: 01/09/2015] [Indexed: 10/24/2022]
Abstract
The Occlutech(®) Figulla(®) septal occluder (OFSO) is a later-generation double-disk device with few reports of its success rates and complications compared with the Amplatzer(®) septal occluder (ASO), which is the worldwide standard device in percutaneous atrial septal defect (ASD) closure. We recruited and compared the results in 149 patients (76.5 % female) who underwent ASD device closure in our center between January 2003 and June 2012. The patients ranged in age from 2.3 to 77.2 years. There were no statistically significant differences between the two groups regarding patient baseline characteristics and procedure variables. The success rate using either device was excellent (ASO 94.4 % and OFSO 97.4 %; p = 0.43). Although the diameter of the ASD and the pulmonary arterial pressure in the OFSO group were slightly higher than in the ASO group, the median fluoroscopic time in the OFSO group was significantly shorter (ASO 13.7 min; OFSO 9.0 min; p < 0.001). The overall median follow-up time was 3.6 years (interquartile range 2.1-9.0 years). There were no significant differences between the major and minor complications when comparing the two devices. Both devices were safe and effective for percutaneous ASD closures. The OFSO had the benefit of a shorter fluoroscopic time.
Collapse
Affiliation(s)
- Supaporn Roymanee
- Pediatric Cardiology Unit, Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand,
| | | | | | | |
Collapse
|
19
|
Transcatheter closure of atrial septal defect with the Figulla® ASD Occluder: A comparative study with the Amplatzer® Septal Occluder. Arch Cardiovasc Dis 2015; 108:57-63. [DOI: 10.1016/j.acvd.2014.09.005] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2014] [Revised: 06/16/2014] [Accepted: 09/09/2014] [Indexed: 11/21/2022]
|
20
|
Aytemir K, Oto A, Özkutlu S, Canpolat U, Kaya EB, Yorgun H, Şahiner L, Sunman H, Ateş AH, Kabakçı G. Transcatheter interatrial septal defect closure in a large cohort: midterm follow-up results. CONGENIT HEART DIS 2013; 8:418-27. [PMID: 23601507 DOI: 10.1111/chd.12057] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/27/2013] [Indexed: 12/12/2022]
Abstract
OBJECTIVES We evaluated immediate and midterm results of transcatheter closure of atrial septal defects (ASDs) and patent foramen ovale (PFO) using various closure devices. MATERIALS AND METHODS The study included four hundred fourteen patients (one hundred eighty-two men, two hundred thirty-two women; mean age 39 ± 12.3 years; range 17-67 years) who underwent transcatheter closure of secundum ASD (n = 193) or PFO (n = 221). All the patients were evaluated by transthoracic echocardiography and transesophageal echocardiography before the procedure. Transcatheter closure was performed by using Amplatzer (n = 184), Occlutech Figulla (n = 209), or BioSTAR (n = 21) devices. Closure of ASDs was performed under general anesthesia with transesophageal echocardiography guidance, and closure of PFOs was performed under local anesthesia with transthoracic echocardiography guidance. Follow-up controls were at 1, 6, and 12 months and annually thereafter. The median follow-up periods of ASD and PFO patients were 43 and 30 months. RESULTS The mean device size was 19.3 ± 6.2 mm for ASD patients and 24.6 ± 2.6 mm for PFO patients. The mean procedural and fluoroscopy times were 22.3 ± 4.7 and 4.1 ± 1.9 minutes for ASD closure and 12.4 ± 3.2 and 3.1 ± 1.2 minutes for PFO closure, respectively. Procedural device embolization occurred in only two patients (0.48%). During follow-up, recurrent embolic events occurred in four patients (1.8%) after PFO closure, and no residual shunts were seen after ASD closure. Device thrombosis developed in two ASD patients during the procedure and in one PFO patient at 12th month of the follow-up (0.72%). CONCLUSION Transcatheter closure of PFOs and secundum-type ASDs using the Amplatzer, Occlutech Figulla, and BioSTAR devices is an efficacious and safe therapeutic option.
Collapse
Affiliation(s)
- Kudret Aytemir
- Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara
| | | | | | | | | | | | | | | | | | | |
Collapse
|